journal article·2025-08Open access

Ezetimibe Engineered L14‐8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53‐ SAT1 ‐Induced Ferroptosis

Yu Zhang, Xiao‐wen Song, Na Zhang, Xue‐hui Li, Fan‐chen Wu, Yu‐ang Wei, Dong‐liang Xu, Ling‐fan Xu, Fu‐wen Yuan

Advanced Science· Volume 12· Issue 29

Abstract

Abstract Androgen receptor signaling inhibitors (ARSIs) have demonstrated a survival benefit in metastatic prostate cancer. However, patients taking these agents inevitably acquire resistance and even develop neuroendocrine prostate cancer (NEPC), in which stage the AR signaling is inactive, and therapies are limited for these lethal cases. Therefore, developing novel treatments independent of the AR signaling pathway is urgently needed. Here it is reported that L14‐8, a small molecule is derived and optimized from ezetimibe, a marketed drug primarily used for intestinal cholesterol and phytosterol absorption, significantly suppresses cell growth in advanced prostate cancer by inducing ferroptosis. Mechanistically, L14‐8 binds to and promotes the ubiquitin‐mediated PLK1 degradation, resulting in an increase of downstream TP53 protein phosphorylation, which is further enriched at the promoter of SAT1 , a well‐established ferroptosis inducer, and boosting SAT1 transcription thus triggers ferroptosis‐mediated cancer cell death. Importantly, in vivo studies further demonstrate a potent anti‐tumor efficacy of L14‐8 without obvious toxicity. Overall, this study develops a novel small molecular engineered from ezetimibe for treating lethal prostate cancer in an AR‐independent manner and provides mechanistic insights into its action by triggering PLK1‐TP53‐ SAT1 axis‐mediated ferroptosis in lethal PCa models independent of the AR signaling pathway.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer-related gene regulation · Ferroptosis and cancer prognosis · Prostate Cancer Treatment and Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology Institute of Interdisciplinary Integrative Medicine Research Shanghai University of Traditional Chinese Medicine Shanghai 201203 China

School of Chemistry and Chemical Engineering Henan Normal University Xinxiang Henan 453007 China

The Center for Cancer Research School of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai 201203 China

Department of Laboratory Medicine Shanghai East Hospital Tongji University School of Medicine Shanghai 200123 China

Shanghai TCM‐Integrated Hospital Shanghai University of Traditional Chinese Medicine Shanghai 200082 China

Department of Urology Shuang Hospital Shanghai University of Traditional Chinese Medicine Shanghai 201203 China

Department of Urology The First Affiliated Hospital of Anhui Medical University Hefei 230001 China

Funding

National Natural Science Foundation of China

References (45)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1093/ajhp/zxac10510.1093/ajhp/zxac105 ↗
3. Verma S. · Cancer Drug Resist. · 2020 · 3 · 742
4. 10.3389/fonc.2019.0085810.3389/fonc.2019.00858 ↗
5. 10.1038/s41419-022-05084-110.1038/s41419-022-05084-1 ↗
6. 10.1200/JCO.2017.77.688010.1200/JCO.2017.77.6880 ↗
7. 10.4103/1008-682X.12366910.4103/1008-682X.123669 ↗
8. 10.1093/nar/gkz79010.1093/nar/gkz790 ↗
9. 10.1038/nature2300710.1038/nature23007 ↗
10. 10.1111/j.1582-4934.2003.tb00210.x10.1111/j.1582-4934.2003.tb00210.x ↗
11. 10.1042/BJ2015016810.1042/BJ20150168 ↗
12. 10.1073/pnas.160715211310.1073/pnas.1607152113 ↗
13. 10.1016/j.freeradbiomed.2018.05.07410.1016/j.freeradbiomed.2018.05.074 ↗
14. 10.1021/acscatal.3c0235010.1021/acscatal.3c02350 ↗
15. 10.1039/D3SC04188C10.1039/D3SC04188C ↗
16. 10.1016/j.chempr.2022.10.00510.1016/j.chempr.2022.10.005 ↗
17. 10.1007/s11426-024-2380-410.1007/s11426-024-2380-4 ↗
18. 10.1016/S0891-5849(02)00848-110.1016/S0891-5849(02)00848-1 ↗
19. 10.1007/978-1-0716-3433-2_610.1007/978-1-0716-3433-2_6 ↗
20. 10.1007/978-1-0716-0247-8_1110.1007/978-1-0716-0247-8_11 ↗
21. 10.1038/s41467-020-15003-710.1038/s41467-020-15003-7 ↗
22. 10.1038/nrm.2016.13210.1038/nrm.2016.132 ↗
23. 10.1146/annurev-biochem-052521-03594910.1146/annurev-biochem-052521-035949 ↗
24. 10.1158/1078-0432.CCR-15-290110.1158/1078-0432.CCR-15-2901 ↗
25. 10.1038/nprot.2014.13810.1038/nprot.2014.138 ↗
26. 10.3389/fphar.2021.71479010.3389/fphar.2021.714790 ↗
27. 10.1016/j.cell.2018.03.06510.1016/j.cell.2018.03.065 ↗
28. 10.1126/science.123360610.1126/science.1233606 ↗
29. 10.1016/j.cmet.2008.04.00110.1016/j.cmet.2008.04.001 ↗
30. 10.1093/oncolo/oyab04510.1093/oncolo/oyab045 ↗
31. 10.1016/j.euo.2023.01.00110.1016/j.euo.2023.01.001 ↗
32. 10.1001/jamaoncol.2024.154910.1001/jamaoncol.2024.1549 ↗
33. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
34. 10.1038/s41580-020-0270-810.1038/s41580-020-0270-8 ↗
35. 10.1038/nature2429710.1038/nature24297 ↗
36. 10.1186/s40170-020-00217-610.1186/s40170-020-00217-6 ↗
37. 10.1016/j.bioorg.2024.10773110.1016/j.bioorg.2024.107731 ↗
38. 10.1080/15412555.2024.234279710.1080/15412555.2024.2342797 ↗
39. 10.1016/j.jep.2023.11633310.1016/j.jep.2023.116333 ↗
40. 10.1016/j.cell.2015.10.02510.1016/j.cell.2015.10.025 ↗
41. 10.1016/j.ccr.2010.05.02610.1016/j.ccr.2010.05.026 ↗
42. 10.1016/j.eururo.2017.08.02710.1016/j.eururo.2017.08.027 ↗
43. 10.1038/nm.404510.1038/nm.4045 ↗
44. 10.1073/pnas.190265111610.1073/pnas.1902651116 ↗
45. 10.1038/srep3371010.1038/srep33710 ↗